We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Global COVID-19 Diagnostics Market to Reach USD 9.94 Billion by Fourth Quarter of 2020

By LabMedica International staff writers
Posted on 30 Oct 2020
The global COVID-19 diagnostics industry was pegged at USD 73.19 million in the first quarter of 2020 and is projected to reach USD 9.94 billion by the fourth quarter of 2020, driven mainly by the rise in COVID-19 patients across the world, need for rapid diagnostics, and lack of specific vaccine or medicine. More...
However, the lack of awareness among developing countries regarding precautions and dearth of diagnostic kits & medical professionals could hinder the market growth. On the contrary, the development of advanced diagnostic kits would open new opportunities for the market players in the future.

These are the latest findings of Allied Market Research (Portland, OR, USA), a full-service market research and business-consulting company.

Researchers have been focusing on developing a potential treatment for COVID-19 and have been conducting months of trials to find the cure, which has increased the demand for COVID-19 diagnostic tools. Since the outbreak of COVID-19, researchers have been working to develop more accurate and faster diagnostic kits. At present, the most widely used diagnostic test for the detection of COVID-19 is reverse transcriptase PCR or RT PCR. PCR is recognized as the gold standard for diagnosis of various infectious agents. The technique has an advantage as the primers required for performing such tests can be produced with relative speed. Moreover, multiplex RT-PCR that has the capability of performing multiple target sequences simultaneously are the most preferred diagnostic tests for COVID-19. In addition, leading manufacturers of diagnostic kits are significantly increasing their capacity to perform such tests by rolling out automated SARS-CoV-2 testing systems. However, a few companies are focusing on developing rapid immunoassay tests for COVID-19 diagnosis.

By product, the PCR kits segment held the lion's share of the global COVID-19 diagnostics industry in the first quarter of 2020, and is expected to maintain its dominance till the end of 2020 due to their high accuracy and specificity. On the basis of technology, the PCR segment accounted for 80% of the total share of the global COVID-19 diagnostics industry in 2020 and is expected to register a prominent growth rate in the near future, owing to its increased demand for diagnosis of coronavirus patients. In addition PCR is considered as a gold standard in terms of diagnosis of new virus infections. However, the immunoassay segment is anticipated to grow at the fastest rate during the forecast period due to the increased demand for rapid immunoassay tests for disease diagnosis.

By end user, the diagnostic labs segment held the largest share of the global COVID-19 diagnostics industry in the first quarter of 2020, contributing to more than two-thirds of the global COVID-19 diagnostics market, due to increased usage of molecular assays for COVID-19 diagnosis as the procedure requires various chemicals and instruments that are more easily available in a diagnostic laboratory. Geographically, Europe held the lion's share of the global COVID-19 diagnostics market in the first quarter of 2020, contributing to nearly half of the total revenue. However, Asia-Pacific is expected to contribute the highest revenue to the global COVID-19 diagnostics industry by the fourth quarter of end of 2020, owing to higher patient population in the region.

Related Links:
Allied Market Research


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.